Introduction
Sickle-cell disease (SCD) results from a variety of inherited genetic mutations in the hemoglobin-beta (HBB) gene resulting in defective beta-globin synthesis and culminating in attenuated oxygen transport (1). One particular HBB gene mutation produces an altered beta-globin molecule known as hemoglobin S (Hb S) with reduced oxygen delivery to end-organs.
Being regarded as a rare clinical entity, SCD in patients who need open heart surgery at large is poorly addressed in literature (2). With diagnostic techniques’advancement, we have encountered many patients with SCD associated with advanced heart failure that necessitates left ventricular assist device (LVAD) implantation. The aim of our present study was to evaluate the outcome of patients with SCD-related hemoglobinopathy undergoing LVAD implantation at our institution and then followed up after hospital discharge. Hence, we decided to retrospectively look into our data to evaluate the outcomes of LVAD implantation in this type of patients .